We can’t show the full text here under this license. Use the link below to read it at the source.
Achievement of HbA1c and weight targets in adults with type 2 diabetes on once weekly injectable glucagon‐like peptide‐1 receptor agonist therapy in UK primary care: A retrospective, real‐world study
Blood sugar and weight goals in adults with type 2 diabetes using weekly injectable diabetes medicine in UK primary care
AI simplified
Abstract
Of 10,816 adults with type 2 diabetes treated with once-weekly injectable glucagon-like peptide-1 receptor agonist therapy, 32.8% achieved glycated haemoglobin () levels below 7% after 6 months.
- Patients diagnosed with type 2 diabetes for less than 5 years had a higher proportion (34.1%) achieving HbA1c < 7% compared to those with longer disease duration.
- Among patients with weight data, 22.0% did not experience any weight loss after 6 months of treatment.
- Weight reductions were observed in 34.0%, 27.0%, 11.4%, and 5.6% of patients, corresponding to weight losses of >0%-<5%, ≥5%-<10%, ≥10%-<15%, and ≥15%, respectively.
- No significant differences in weight loss outcomes were found based on the duration of diabetes.
- Results indicate that a substantial proportion of patients did not meet the HbA1c target or achieve significant weight loss, highlighting a potential gap in diabetes management.
AI simplified
Key numbers
32.8%
< 7% Achievement Rate
Proportion of patients achieving < 7% after 6 months of therapy.
22.0%
Weight Loss Non-Responders
Percentage of patients who did not achieve any weight reduction after 6 months.
61.0%
Patients Not Meeting Dual Targets
Proportion of patients not achieving ≥1% reduction and ≥3% weight loss after 6 months.